94 related articles for article (PubMed ID: 19052976)
1. Clinical relevance of FLT3 gene abnormalities in Brazilian patients with infant leukemia.
Emerenciano M; Menezes J; Vasquez ML; Zalcberg I; Thuler LC; Pombo-de-Oliveira MS;
Leuk Lymphoma; 2008 Dec; 49(12):2291-7. PubMed ID: 19052976
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of FLT3 ITD and D835 mutations in AML patients.
Sheikhha MH; Awan A; Tobal K; Liu Yin JA
Hematol J; 2003; 4(1):41-6. PubMed ID: 12692519
[TBL] [Abstract][Full Text] [Related]
3. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
4. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
5. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Taketani T; Taki T; Sugita K; Furuichi Y; Ishii E; Hanada R; Tsuchida M; Sugita K; Ida K; Hayashi Y
Blood; 2004 Feb; 103(3):1085-8. PubMed ID: 14504097
[TBL] [Abstract][Full Text] [Related]
6. Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy.
Tiesmeier J; Müller-Tidow C; Westermann A; Czwalinna A; Hoffmann M; Krauter J; Heil G; Ganser A; Serve H; Verbeek W
Leuk Res; 2004 Oct; 28(10):1069-74. PubMed ID: 15289019
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of FLT3 in leukemia.
Kiyoi H; Yanada M; Ozekia K
Int J Hematol; 2005 Aug; 82(2):85-92. PubMed ID: 16146837
[TBL] [Abstract][Full Text] [Related]
8. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.
How J; Sykes J; Gupta V; Yee KW; Schimmer AD; Schuh AC; Minden MD; Kamel-Reid S; Brandwein JM
Cancer; 2012 Dec; 118(24):6110-7. PubMed ID: 22736495
[TBL] [Abstract][Full Text] [Related]
9. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
[TBL] [Abstract][Full Text] [Related]
10. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.
Cloos J; Goemans BF; Hess CJ; van Oostveen JW; Waisfisz Q; Corthals S; de Lange D; Boeckx N; Hählen K; Reinhardt D; Creutzig U; Schuurhuis GJ; Zwaan ChM; Kaspers GJ
Leukemia; 2006 Jul; 20(7):1217-20. PubMed ID: 16642044
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.
Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T
Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064
[TBL] [Abstract][Full Text] [Related]
12. Clinical and molecular epidemiology of neonatal leukemia in Brazil.
Moura SV; Andrade F; Magalhães IQ; Costa I; Silva DB; D'Andrea ML; Pinheiro VP; Lee ML; Werneck F; Emerenciano M; Pombo-de-Oliveira MS
Leuk Lymphoma; 2015 Apr; 56(4):903-9. PubMed ID: 24991719
[TBL] [Abstract][Full Text] [Related]
13. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation.
Yoshimoto G; Nagafuji K; Miyamoto T; Kinukawa N; Takase K; Eto T; Kato K; Hayashi S; Kamimura T; Ohno Y; Taniguchi S; Harada M
Bone Marrow Transplant; 2005 Dec; 36(11):977-83. PubMed ID: 16184177
[TBL] [Abstract][Full Text] [Related]
14. FLT3 internal tandem duplication and FLT3-D835 mutation in 80 AML patients categorized into cytogenetic risk groups.
Mały E; Przyborsk M; Nowak T; Nowak J; Januszkiewicz D
Postepy Hig Med Dosw (Online); 2010 Oct; 64():466-70. PubMed ID: 20966504
[TBL] [Abstract][Full Text] [Related]
15. FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.
Chillón MC; Fernández C; García-Sanz R; Balanzategui A; Ramos F; Fernández-Calvo J; González M; Miguel JF
Hematol J; 2004; 5(3):239-46. PubMed ID: 15167911
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia.
Chillón MC; Gómez-Casares MT; López-Jorge CE; Rodriguez-Medina C; Molines A; Sarasquete ME; Alcoceba M; Miguel JD; Bueno C; Montes R; Ramos F; Rodríguez JN; Giraldo P; Ramírez M; García-Delgado R; Fuster JL; González-Díaz M; Menendez P
Leukemia; 2012 Nov; 26(11):2360-6. PubMed ID: 22705992
[TBL] [Abstract][Full Text] [Related]
17. Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene.
Yoo SJ; Park CJ; Jang S; Seo EJ; Lee KH; Chi HS
Leuk Lymphoma; 2006 Sep; 47(9):1788-93. PubMed ID: 17064989
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
[TBL] [Abstract][Full Text] [Related]
20. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
